Key Insights

Highlights

Success Rate

77% trial completion

Published Results

17 trials with published results (14%)

Research Maturity

58 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.3%

17 terminated out of 119 trials

Success Rate

77.3%

-9.2% vs benchmark

Late-Stage Pipeline

7%

8 trials in Phase 3/4

Results Transparency

29%

17 of 58 completed with results

Key Signals

17 with results77% success17 terminated

Data Visualizations

Phase Distribution

88Total
Not Applicable (24)
Early P 1 (3)
P 1 (27)
P 2 (26)
P 3 (5)
P 4 (3)

Trial Status

Completed58
Terminated17
Recruiting17
Unknown15
Withdrawn7
Active Not Recruiting3

Trial Success Rate

77.3%

Benchmark: 86.5%

Based on 58 completed trials

Clinical Trials (119)

Showing 20 of 20 trials
NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT06916715Active Not RecruitingPrimary

MR Elastography in Intracranial Lesions: Feasibility & Accuracy

NCT07499141Completed

Use of Fluorescence in Gliomas

NCT06165653Not ApplicableRecruitingPrimary

Guided Meditation During Radiation Therapy for Brain Tumors

NCT06322602Not ApplicableRecruitingPrimary

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors

NCT07426848Not ApplicableRecruiting

OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients

NCT07238322Active Not Recruiting

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

NCT05386108Phase 1Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT07272616RecruitingPrimary

Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

NCT05049148Not ApplicableRecruiting

Platelets Activation in Brain Neoplasms

NCT06322342Phase 2Completed

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

NCT05770544Phase 2Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT06930846Not ApplicableRecruiting

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

NCT07111182Not ApplicableRecruitingPrimary

Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery

NCT04543188Phase 1Terminated

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04712721Early Phase 1Terminated

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

NCT01931098Phase 2Completed

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

NCT06128148Phase 1Recruiting

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

NCT07046481Not ApplicableWithdrawn

Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up

NCT04940507Not ApplicableActive Not RecruitingPrimary

BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial

Scroll to load more

Research Network

Activity Timeline